Connect
MJA
MJA

Upper limb tremor

Thomas E Kimber and Philip D Thompson
Med J Aust 2012; 196 (7): 447-451. || doi: 10.5694/mja11.11565
  • Thomas E Kimber1,2
  • Philip D Thompson1,2

  • 1 Royal Adelaide Hospital, Adelaide, SA.
  • 2 University of Adelaide, Adelaide, SA.


Competing interests:

Thomas Kimber serves on Medical Advisory Boards for Hospira, Abbott and Biogen Idec and has received funding for travel from Novartis. Philip Thompson has served on the Medical Services Advisory Committee and on Medical Advisory Boards for Lundbeck, Boehringer Ingelheim, Novartis, Ipsen and Allergan; he has received funding for travel and an honorarium for educational lectures at a meeting sponsored by UCB Pharma; and he is Past President of the Movement Disorder Society.

  • 1. Schwingenschuh P, Schneider S, Silveira-Moriyama L, et al. Adult-onset dystonic tremor as differential diagnosis for Parkinson’s disease: detailed clinical description of 20 patients emphasizing non-motor symptoms including olfactory function. Parkinsonism Relat Disord 2007; 13 Suppl 2: S70-S71.
  • 2. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling Parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22: 2210-2215.
  • 3. Hayes MW, Fung VS, Kimber TE, O’Sullivan JD. Current concepts in the management of Parkinson disease. Med J Aust 2010; 192: 144-149. <MJA full text>
  • 4. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996; 46: 388-392.
  • 5. Schenck CH, Bundlie SR, Mahowald MW. REM sleep behaviour disorder (RBD) delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the maximum and minimum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003; 26 (Suppl): A316.
  • 6. Schrag A, Dodel, Spottke A, et al. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 2007; 22: 938-945.
  • 7. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of PD as determined by serial positron emission tomographic imaging of striatal flurodopa F 18 activity. Arch Neurol 2005; 62: 378-382.
  • 8. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
  • 9. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
  • 10. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004; 351: 2498-2508.
  • 11. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-1661.
  • 12. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009; 361: 1268-1278.
  • 13. Tanaka K, Quadros AC Jr, Santos RF, et al. Benefits of physical exercise on executive functions in older people with Parkinson’s disease. Brain Cogn 2009; 69: 435-441.
  • 14. Cruise KE, Bucks RS, Loftus AM, et al. Exercise and Parkinson’s: benefits for cognition and quality of life. Acta Neurol Scand 2011; 123: 13-19.
  • 15. Kwakkel G, de Goede CJT, van Wegen EEH. Impact of physical therapy for Parkinson’s disease: a critical review of the literature. Parkinsonism Relat Disord 2007; 13 Suppl 3: S478-S487.
  • 16. Kempster PA, Williams DR, Selikhova M, et al. Patterns of levodopa use in Parkinson’s disease: a clinico-pathological study. Brain 2007; 130: 2123-2128.
  • 17. Parkkinen L, O’Sullivan SS, Kuoppamaki M, et al. Does levodopa accelerate the pathologic process in Parkinson’s disease brain? Neurology 2011; 77: 1420-1426.
  • 18. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
  • 19. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson’s disease. Mov Disord 2009; 24: 1561-1570.
  • 20. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254-1257.
  • 21. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications in Parkinson’s disease: longterm follow-up study of 64 patients. Mov Disord 2002; 17: 1235-1241.
  • 22. Garcia Ruiz PJ, Ignacio AS, Pensado BA, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicentre study. Mov Disord 2008; 23: 1130-1136.
  • 23. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-163.
  • 24. Nyholm D, Nilsson Remahl AIM, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
  • 25. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006; 355: 896-908.
  • 26. Moro E, Lozano AM, Pollak P, et al. Long-term results of a mulicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord 2010; 25: 578-586.
  • 27. Castrioto A, Lozano AM, Poon Y, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011; 68: 1550-1556.
  • 28. Rodriguez-Oroz MC, Obeso JA, lang AE, et al. Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 2005; 128: 2240-2249.
  • 29. Derost P, Ouchchane L, Morand D, et al. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 2007; 68: 1345-1355.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.